In a recent announcement, US pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) unveiled the latest five-year results from its POETYK PSO long-term extension study. The study evaluates the sustained efficacy and safety of Sotyktu (deucravacitinib), a groundbreaking treatment for adults with moderate-to-severe plaque psoriasis.
Sotyktu, recognized as the world’s first and only allosteric tyrosine kinase 2 (TYK2) inhibitor, has garnered approvals in multiple countries for treating adult patients with moderate-to-severe plaque psoriasis. The newly released data highlight the consistent safety profile of Sotyktu over a five-year period, supported by more than 5,000 patient-years of exposure in clinical trials. Importantly, no new safety signals were identified during this extensive study.
The findings also underscore the sustained clinical response rates among patients continuing treatment with Sotyktu throughout the first to fifth years of the study. Key metrics include:
- PASI 75: Maintained at 72.1% in the first year and 67.3% in the fifth year.
- PASI 90: Consistent at 45.9% in the first year and 46.3% in the fifth year.
- sPGA 0/1: Demonstrated at 57.5% in the first year and 52.6% in the fifth year.
These results reaffirm Sotyktu’s role as a reliable long-term treatment option for patients with moderate-to-severe plaque psoriasis, further solidifying its position in the dermatology landscape.-Fineline Info & Tech
